Moderna, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Moderna, Inc. (MRNA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 42.00 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-31
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 42.00M shares, a 8.70% decline year-over-year.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 45.00M shares, a 8.16% decline year-over-year.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 45.00M shares, a 309.09% increase year-over-year.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 46.00M shares, a 35.29% increase year-over-year.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 38.00M shares, a 11.76% increase from fiscal 2024.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 34.00M shares, a 9.68% increase from fiscal 2023.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 31.00M shares, a 933.33% increase from fiscal 2022.
- Moderna, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.00M shares, a 200.00% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 42.00M shares 10-Q · filed 2026-07-31 | 42.00M shares 10-Q · filed 2026-07-31 | ||||||
| 2026-03-31 | 45.00M shares 10-Q · filed 2026-05-01 | |||||||
| 2025-12-31 | 38.00M shares 10-K · filed 2026-02-20 | |||||||
| 2025-09-30 | 45.00M shares 10-Q · filed 2025-11-06 | 45.00M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 46.00M shares 10-Q · filed 2026-07-31 | 46.00M shares 10-Q · filed 2026-07-31 | ||||||
| 2025-03-31 | 49.00M shares 10-Q · filed 2026-05-01 | |||||||
| 2024-12-31 | 34.00M shares 10-K · filed 2026-02-20 | |||||||
| 2024-09-30 | 11.00M shares 10-Q · filed 2025-11-06 | 33.00M shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 34.00M shares 10-Q · filed 2025-08-01 | 34.00M shares 10-Q · filed 2025-08-01 | ||||||
| 2024-03-31 | 35.00M shares 10-Q · filed 2025-05-01 | |||||||
| 2023-12-31 | 31.00M shares 10-K · filed 2026-02-20 | |||||||
| 2023-09-30 | 28.00M shares 10-Q · filed 2024-11-07 | 28.00M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 28.00M shares 10-Q · filed 2024-08-01 | 28.00M shares 10-Q · filed 2024-08-01 | ||||||
| 2023-03-31 | 5.00M shares 10-Q · filed 2024-05-02 | |||||||
| 2022-12-31 | 3.00M shares 10-K · filed 2025-02-21 | |||||||
| 2022-09-30 | 4.00M shares 10-Q · filed 2023-11-03 | 3.00M shares 10-Q · filed 2023-11-03 | ||||||
| 2022-06-30 | 4.00M shares 10-Q · filed 2023-08-03 | 3.00M shares 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | 2.00M shares 10-Q · filed 2023-05-04 | |||||||
| 2021-12-31 | 1.00M shares 10-K · filed 2024-02-23 | |||||||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-03 | 1.00M shares 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | 1.00M shares 10-Q · filed 2022-08-03 | 1.00M shares 10-Q · filed 2022-08-03 | ||||||
| 2020-12-31 | 36.00M shares 10-K · filed 2023-02-24 | 36.25M shares 10-K · filed 2021-02-26 | ||||||
| 2020-09-30 | 39.00M shares 10-Q · filed 2021-11-04 | 39.43M shares 10-Q · filed 2020-10-30 | ||||||
| 2020-06-30 | 42.00M shares 10-Q · filed 2021-08-05 | 41.70M shares 10-Q · filed 2020-08-06 | ||||||
| 2020-03-31 | 47.00M shares 10-Q · filed 2021-05-06 | 47.05M shares 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | 47.00M shares 10-K · filed 2022-02-25 | 46.71M shares 10-K · filed 2020-02-27 | ||||||
| 2019-09-30 | 50.64M shares 10-Q · filed 2020-10-30 | |||||||
| 2019-06-30 | 53.15M shares 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 54.43M shares 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 51.48M shares 10-K · filed 2021-02-26 | |||||||
| 2018-09-30 | 280.85M shares 10-Q · filed 2019-11-06 | |||||||
| 2018-06-30 | 281.26M shares 10-Q · filed 2019-08-08 | |||||||
| 2017-12-31 | 240.38M shares 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | 233.84M shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |